

Comprehensive Medication Management Practice Management Assessment Tool

January, 2018

Acknowledgements

This work was supported by the American College of Clinical Pharmacy (ACCP) and the ACCP Research Institute through the grant Enhancing Performance in Primary Care Medical Practice through Implementation of Comprehensive Medication Management. The authors gratefully acknowledge all the pharmacists and primary care practices engaged in this study for their valuable work and insights.

Table of Contents

Background and Guidance for Use1					
Part I – Global Assessment of the Domains of CMM Practice Management	. 3				
Part II – Assessing the Domains and Essential Components of CMM Practice Management					
Organizational Support	7				
Care Team Engagement	10				
Care Delivery Processes	14				
CMM Program Evaluation	19				
Ensuring Consistent and Quality Care	22				
Part III – Prioritizing and Guiding Areas for Improvement	24				
Glossary	25				

Background and Guidance for Use

Purpose

This is a tool used to assess and prioritize areas of improvement for comprehensive medication management (CMM) practice management (i.e., the necessary resources and support to provide CMM in a proficient and productive manner). While pharmacists may engage in many patient care services (e.g., disease state management, patient education, annual wellness visits), this tool was designed to specifically assess CMM.

What is Comprehensive Medication Management?

Comprehensive medication management (CMM) is defined as:

The standard of care that ensures each patient's medications (whether they are prescription, nonprescription, alternative, traditional, vitamins, or nutritional supplements) are individually assessed to determine that each medication is appropriate for the patient, effective for the medical condition, safe given the comorbidities and other medications being taken, and able to be taken by the patient as intended. CMM includes an individualized care plan developed in collaboration with the health care team and the patient that achieves the intended goals of therapy with appropriate follow-up to determine actual patient outcomes. This all occurs because the patient understands, agrees with, and actively participates in the treatment regimen, thus optimizing each patient's medication experience and clinical outcomes.¹

The practice of CMM is comprised of three key elements



Philosophy of practice

- 1. Philosophy of practice: The professional values and beliefs held by practitioners that guide their actions and decisions in practice
- 2. Patient care process: The step-by-step process of delivering CMM
- 3. Practice management: The necessary resources and support to provide CMM in a proficient and productive manner

© CMM in Primary Care Research Team

1

Structure of the practice management tool

This tool consists of three parts:

- Part I: A global assessment of all domains of CMM practice management to prioritize areas for further assessment
- Part II: A comprehensive assessment tool of all domains and essential components of CMM practice management
- Part III: A worksheet to identify and guide areas of practice improvement after completing part II

Guidance for use

This tool is meant to be filled out for an individual practice site by the CMM pharmacist(s) who work there. However, some questions may require input from other members of the team (e.g., clinic or health system manager, CMM manager). Depending on the practice setting, some questions may not apply. It is recommended that this tool be completed, in whole or in part, at least once a year for an individual clinic to guide continual practice development.

Part I – Global Assessment of the Domains of CMM Practice Management

Directions: There are five domains of CMM practice management: (1) Organizational support, (2) Care team engagement, (3) Care delivery processes, (4) CMM program evaluation, and (5) Ensuring consistent and quality care. To determine which domains to focus on, please rate how well your CMM practice performs and the feasibility for improvement within the following domains.

Organizational support

When thinking of *organizational support*, consider the following:

How well does your leadership (both clinic level and executive) understand CMM? Does your leadership support and champion CMM? Do they support you in obtaining necessary resources? Do you have adequate patient care and non-patient care workspace dedicated to you? Are your services aligned with value-based payment?

Performance: On a scale of 0-10, with 10 being most optimal, how would you rate organizational support for your CMM practice?

0	1	2	3	4	5	6	7	8	9	10

<u>Feasibility</u>: On a scale of 0-10, with being 10 being most feasible, how would you rate the feasibility of improving *organizational support* of your CMM practice?

				7		

Care team engagement

When thinking of *care team engagement*, consider the following:

How would you rate your level of collaboration and communication with the rest of the care team? Do they have a good understanding of CMM? Do you receive referrals from most clinic providers? Do you have collaborative practice agreements in place that allow you to initiate, modify, and discontinue medications from numerous conditions and drug classes? Do you have designated support staff to room and take vitals of your CMM patients?

Performance: On a scale of 0-10, with 10 being most optimal, how would you rate your care team's engagement with CMM?

0	1	2	3	4	5	6	7	8	9	10

Feasibility: On a scale of 0-10, with being 10 being most feasible, how would you rate the feasibility of improving your care team's engagement with CMM?

			5			

Care delivery processes

When thinking of *care delivery processes*, consider the following:

Are you responsible for identifying most of your CMM patients? Do you use tools such as algorithms to identify patients most in need of CMM? Are these algorithms built into the EHR to maximize efficiency? Are there automated pop-ups for patients in need of CMM? Does your EHR allow you to identify and manage a panel of CMM patients? Is there a process in place to ensure patients complete follow-up visits? Do you receive assistance with scheduling patient visits? Are you double documenting? Are efficiency tools for documentation built into the EHR such as clinical decision support (e.g., computerized alerts and reminders, condition-specific order sets)?

Performance: On a scale of 0-10, with 10 being most optimal, how would you rate your care delivery processes of CMM?

0	1	2	3	4	5	6	7	8	9	10

<u>Feasibility</u>: On a scale of 0-10, with being 10 being most feasible, how would you rate the feasibility of improving *care delivery processes* in your CMM practice?

	2				

CMM program evaluation:

When thinking of CMM program evaluation, consider the following:

Is the identification and resolution of medication therapy problems being tracked? Are other CMM measures such as clinical markers, patient satisfaction, and pharmacist productivity being tracked? Are the data that are being collected from these measures being used to enhance and improve the CMM practice? Are results being reported to the clinic, leadership, and/or external audiences (e.g., presentations, publications)?

Performance: On a scale of 0-10, with 10 being most optimal, how would you rate your CMM program evaluation?

0	1	2	3	4	5	6	7	8	9	10

<u>Feasibility</u>: On a scale of 0-10, with being 10 being most feasible, how would you rate the feasibility of improving *CMM program evaluation* in your CMM practice?

0	1	2	3	4	5	6	7	8	9	10

Ensuring consistent and quality care:

When thinking of ensuring consistent and quality care, consider the following:

If a new pharmacist is hired, do you have a consistent training process in place to ensure that they are well trained on the philosophy of CMM practice and the patience care process? Does your employer provide you with money and time for continuing professional development? Do you receive consistent retraining on CMM? Do you have a process in place to ensure that your documentation is clinically sound and accurately completed (i.e. quality assurance)? If you have a process, is the information gleaned used to improve your CMM practice?

Performance: On a scale of 0-10, with 10 being most optimal, how would you rate ensuring consistent and quality care of your CMM practice?

			5			

<u>Feasibility</u>: On a scale of 0-10, with being 10 being most feasible, how would you rate the feasibility of improving *ensuring consistent and quality care* in your CMM practice?



Preparing for part II: Comprehensive assessment tool

Below, write down the score that you gave each of the domains of CMM practice management. Taking into consideration performance and feasibility, select the two domains that you think would be most relevant to focus on improving. Answer all the questions that pertain to those two domains on the corresponding page numbers listed below.

Optional: For a more through practice management assessment, you may complete the entire assessment tool answering the questions for all five domains

Domain	Performance score	Feasibility score	Domain questions available on
Organizational support			(p. 7-9)
Care team engagement			(p. 10-13)
Care delivery processes			(p. 14-18)
CMM program evaluation			(p. 19-21)
Ensuring consistent and quality care			(p. 22-23)

Part II – Assessing the Domains and Essential Components of CMM Practice Management

Organizational Support

Directions: Listed below are the essential components of organizational support. For each item listed under the essential component, mark the box that best describes your current CMM practice.

	Less Of	Jumai						Opuillai
Availability and ac	equac	y of clinic spa	ace					
Availability of patient care space	desig each CMI is so to fi	re is NOT a gnated room for a pharmacist to see M patients AND it ometimes difficult and space to see ents in a timely ion	designa each ph CMM 1 finding patient	s NOT a tited room for narmacist to see patients, BUT a room to see s in a timely t is never an	0	There is a desig room for each pharmacist that available to see patients	is	• There are two or more designated rooms for each pharmacist that are available to see CMM patients
Availability of non- patient care space	patie	re is NOT designated ent care workspace av CMM pharmacists		There is non-pa workspace avail pharmacists, BI easily accessible frequent comm care team meml	lable <u>UT</u> e (i.e. unic	e to CMM it is <u>NOT</u> a, to facilitate cation) to other	wor phar acce	re is non-patient care kspace available to CMM rmacists <u>AND</u> it is easily essible to other health care team nbers
Privacy of space	requ	re is <u>NOT</u> space that hirements for <u>ALL</u> CN -to-face, phone, or vie	MM visits, w	•	0	*		es privacy requirements for er they are face-to-face, phone,

Less optimal

Optimal

Size of space	0	Rooms are NOT large en people that may be prese pharmacist, patient, fami	nt di	uring CMM (e.g.,	0	• Rooms are large enough to comfortably fit all people that may be present during CMM (e.g., pharmacist, patient, family members, interpreters)							
Care space equipment	0	Rooms do <u>NOT</u> have no CMM needs (e.g., desk sp medications, computer, p	pace	for patient's	0	Rooms have necessary equipment to meet CMM needs (e.g., desk space for patient's medications, computer, phone)							
Leadership support	Leadership support												
Source of support • Clinical pharmacy manager	0	Not applicable, there is not a clinical pharmacy manager for CMM	0	The clinical pharmacy manager has a good understanding of CMM	0	The clinical pharmacy manager has a good understanding of AND supports (e.g., responds to barriers, ensures necessary resources are available) CMM	0	The clinical pharmacy manager has a good understanding of <u>AND</u> supports (e.g., responds to barriers, ensures necessary resources are available) <u>AND</u> champions CMM (e.g., proactively advocates for the practice)					
Source of support • Clinic leadership (e.g., lead physician, clinic manager)	0	In general, clinic leadership does <u>NOT</u> have a good understanding or support CMM	0	In general, clinic leadership has a good understanding of CMM	0	In general, clinic leadership has a good understanding of <u>AND</u> supports (e.g., respond to barriers, ensure necessary resources are available) CMM	0	In general, clinic leadership has a good understanding of <u>AND</u> supports (e.g., respond to barriers, ensure necessary resources are available) <u>AND</u> champions CMM (e.g., proactively advocates for the practice)					

Source of support Executive leadership 	 In general, executive leadership does NOT have good understanding or support CMM CMM C
Form of support	 In what ways does leadership (pharmacy, clinic, or executive leadership) support CMM pharmacists? (Check all that apply) CMM pharmacists' presence in the clinic Participation in provider meetings Clinic space Recruiting CMM patients Scheduling CMM patients Encouraging use among other care team members of CMM services CMM pharmacists working at the top of their licenses Supplying equipment (e.g., phone, blood pressure cuff) Addressing concerns related to CMM operations or service delivery Advocating for resources (e.g., informatics time)
Finances	
CMM revenue (Check all that apply)	 Pharmacists bill fee-for-service off non-pharmacy mechanisms (e.g., Medicare annual wellness visits or incident-to) Increased clinic revenue is generated because pharmacists engage in co-visits with providers allowing them to bill at a higher level Pharmacists bill fee-for-for-service through pharmacy mechanisms (e.g., MTM CPT codes) Pharmacists or bill at a higher level Pharmacists bill fee-for-service through pharmacy mechanisms (e.g., MTM CPT codes)

Care Team Engagement

Directions: Listed below are the essential components of care team engagement. For each item listed under the essential component, mark the box that best describes your current CMM practice.

Less optimal Optimal Interprofessional collaboration Communication with There is a consistent There is **NOT** a consistent There is a consistent 0 0 0 providers communication strategy for communication strategy for communication strategy for contacting providers with contacting providers with CMM contacting providers with CMM recommendations AND ensuring recommendations CMM recommendations recommendations are followed through **Collaborative visits** Not applicable; If a collaborative visit If a collaborative visit If a collaborative visit 0 0 0 0 collaborative visits do occurs, there is **NOT** a occurs, there is a occurs, there is a defined • Workflow defined workflow that defined workflow that workflow that is not occur is consistently executed is **SOMETIMES CONSISTENTLY** for seeing those executed for seeing executed for seeing those those patients patients patients **Collaborative visits** Not applicable; After a collaborative When conducting 0 0 When conducting 0 0 collaborative visits, there collaborative visits do patient visit is collaborative visits, • Implementing complete, there are **SOMETIMES** there are **CONSISTENTLY** not occur collaborative care are defined roles that defined roles that **NO** defined roles that plans articulate which articulate which articulate which member member of the care member of the care of the care team is team is responsible for team is responsible for responsible for executing executing various parts executing various parts various parts of the CMM of the CMM care plan of the CMM care plan care plan (e.g., who will (e.g., who will send (e.g., who will send send prescriptions, prescriptions, educate prescriptions, educate educate the patient) the patient) the patient)

10

Organizational presence	0	CMM pharmacists are consistently invited to clinic meetings			1	ists are consister d clinic meeting	s in <u>4</u>	nvited to a ND CMN	M pharmacists are consistently ted to attend clinic meetings D CMM is represented in mization-wide clinical program tings			
Champion	0	Within the care team, pharmacist champion			non-	• Within the care team, there is at least one non-pharmacist champion of CMM services						
Direct provider referrals	0	Currently, <u>NO</u> providers within the clinic refer patients for CMM	in clinic	providers $0, \le 25\%$ tients for	in c	the providers Elinic, 26-50% er patients for IM	nic, 26-50% in clinic, 51-75% in patients for refer patients for 1					
Placing new referrals to other care team members	0	CMM pharmacists <u>C</u> other care team mem	•		errals to	• CMM pharmacists can place new referrals to other care team members in the EHR						
Orienting new care team members	0	When a new (non-ph hired, there is NOT a them to CMM (e.g., s discussing patients to	a process in shadowing o	place to orio pportunities	ent	 When a new (non-pharmacist) care team member is hired, there is a process in place to orient them to CMM (e.g., shadowing opportunities, discussing patients to refer for CMM) 						
Presence and scor	be o	of collaborative	e practio	ce agree	ment	s (CPAs)						
 Medications Ability to adjust dosing of existing medications (Check all that apply) 		Pharmacists do NO1 have a protocol or CPA to adjust dosing of any medication(s)	g me an def	armacists ca sing of edication(s) t algorithm w fined series o ions (e.g. pr	through vith a of	dosing of through <u>c</u> specific (hypertens	sts can adjust medication(s) ondition- CPAs (e.g., ion, diabetes) ow for clinical naking	d t <u>li</u> c	 Pharmacists can adjust dosing of medication(s) through <u>broad CPAs</u> <u>limited only by the</u> <u>exclusion of certain</u> <u>drug classes or</u> <u>conditions</u> 			

 Medications Ability to initiate or discontinue medications (Check all that apply) 		Pharmacists do NOT have a protocol or CPA to initiate or discontinue any medication(s)	initia medi an alı defin	te or catio gorit ed s	nacists can e or discontinue cation(s) through corithm with a ed series of as (e.g. protocol)		 Pharmacists can or discontinue medication(s) that <u>condition-speci</u> <u>CPAs</u> (e.g., hype diabetes) which a clinical decision 		h sion, 7 for	 Pharmacists can initiate or discontinue medication(s) through <u>broad CPAs limited</u> <u>only by the exclusion</u> <u>of certain drug classes</u> <u>or conditions</u> 	
Labs	0	Pharmacists <u>CANNOT</u> of any lab monitoring	order	0	<u>ALL</u> labs ord	rmacists can order labs, <u>BUT</u> L labs ordered by a pharmacist l provider approval			monito	acists can order lab oring <u>WITHOUT</u> provider al under their CPA	
Durable medical equipment (DME) (e.g., blood pressure cuff)	0	Pharmacists CANNOT of any DME	order	0	but all D	Pharmacists can order DME, BUT ALL DME ordered by a pharmacist needs provider approval			WITE	nacists can order DME <u>HOUT</u> provider approval their CPA	
Imaging (e.g., DXA scan)	0	Pharmacists CANNOT of any imaging	order	0	Pharmacists can order imaging, <u>BUT ALL</u> imaging ordered by a pharmacist needs provider approval			 Pharmacists can order imaging <u>WITHOUT</u> a provider co- signature under their CPA 			
Support staff (These interns)	e ro	les could be fulfilled by	⁷ multipl	e te	am members	s, sı	ich as MAs, nu	rses	, pharn	nacy techs, pharmacy	
Scheduling encounters (Check all that apply)		There is support staff to s CMM referrals • Yes, but only for so patients • Yes, support staff so <u>ALL</u> CMM referrals	ome		 Yes, but staff is ava prospectiv identified j Yes, and staff is ava 	scho from not ilabl ely s patie suf ilabl ely s	edule CMM n lists of patients enough support e to schedule all ents ficient support e to schedule <u>ALL</u>		CMM appoint o Y pat o Y <u>AL</u>	is support staff to schedule patient follow-up ntments Yes, but only for some tients Yes, support staff schedule <u>L</u> CMM follow-up pointments	

Rooming	 Pharmacists are respon rooming <u>ALL</u> CMM participation 		• Pharmacists have support staff to rooming SOM		sup	rmacists have dedicated port staff to assist with ming <u>ALL</u> CMM patients				
Vitals	 Pharmacists are respon taking necessary vitals of CMM patients 			ve dedicated assist with taking of <u>SOME</u> CMM	sup	armacists have dedicated oport staff to assist with taking cessary vitals for <u>ALL</u> CMM tients				
Billing and coding	 Not applicable, pharma not bill for CMM 	cists do		e responsible for ng and coding for MM patients	pro	rmacists have support staff to cess billing for reimbursable M patients				
Point of care testing	 Pharmacists perform al testing 	l their own p	oint-of-care		Pharmacists can utilize staff support to perform point- of-care testing					
Dedicated support person (e.g., MA, LPN)	 Pharmacists have no staff resources available 	clinic o fro su o su eff	nacists can use staff, if available I would benefit om additional staff pport resources I have sufficient pport staff to ficiently provide MM	 Pharmacists sl staff with the st the care team I would from addi staff supp resources I have s support st efficiently CMM 	rest of benefit tional ort ufficient aff to	 Pharmacists have dedicated CMM staff I would benefit from additional staff support resources I have sufficient support staff to efficiently provide CMM 				
Additional staff support										

Care Delivery Processes

Directions: Listed below are the essential components of care delivery processes. For each item listed under the essential component, mark the box that best describes your current CMM practice.

Less optimal

Identifying patient	nts	for CMM			-				
Pharmacist identification	0	Pharmacists are responsible for identifying <u>MOST</u> CMM patients	0	 Other methods exist (e.g., algorithm, referrals) so that pharmacists are <u>NOT</u> responsible for identifying <u>MOST</u> CMM patients 					
Applying an algorithm <i>(Check all that apply)</i>		There are NO criteria to prospectively identify patients in highest need of CMM There are criteria to identify patients in highest need of CMM that must be manually applied		There is an automated algorithm that is used periodically to prospectively identify patients in highest need of CMM. Manual outreach is needed to schedule these patients for a CMM visit	□ There is an automated algorithm that identifies patients in highest need of CMM and produces an alert in the course of care (e.g., a pop-up alert in the EHR) to encourage provider referral of the patient for a CMM visit.				
Non-provider referrals (e.g. desk staff, community pharmacy, case managers, protocol- based nurse service)	0	Non-providers do <u>NOT</u> identify patients who would be good candidates for CMM	0	 Non-providers identify patients who would be good candidates for CMM 					
Payer referrals	0	NO CMM patients are identified by payer referrals	0	• CMM patients are identified by payer referrals					
Generated quality care lists	0	NO CMM patients are identified by clinic generated lists or registries based on quality measures	• CMM patients are identified by clinic generated lists registries based on quality measures						

Patient panels	 The EHR does <u>NOT</u> allow Pharmacists use the EHR to pharmacists to identify the patients who have been seen for CMM by creating their own CMM panel <u>OR</u> the EHR allows CMM empanelment, but pharmacists do not use it Pharmacists use the EHR to identify patients who have received CMM and assign them to a panel Pharmacists use the EHR to identify <u>AND</u> manage a patients who are received to a panel 	panel of									
Scheduling CMM visits											
Scheduling in EHR	• The EHR does <u>NOT</u> enable CMM scheduling • The EHR enables CMM scheduling										
Referrals	• There is NOT a referral system for CMM in place • There is a referral system for CMM o There is a referral system for CMM in place within the EHR										
Automatic appointment reminder	 There are NOT automatic appointment reminders generated for patients for CMM visits There are automatic appointment reminders generated for patients for CMM visits 	enerated									
Follow up	• There is NOT a process in place to ensure patients complete recommended follow-up visit(s)• There is a manual process in place to ensure patients complete recommended follow-up visit(s)• There is a nautomated p place to ensure patients complete recommended follow-up visit(s)	complete									
Appointment management	 There is NOT a systematic approach to track appointments There is a systematic approach to track appointments How many initial appointments turn into completed visits How many completed visits result in sch follow up appointments How many targeted patients (e.g., cold c patients or sending out letters) turn into convisits How many no shows turn into completed visits In-person visits vs. remote Initial encounter vs. follow up visit 	o neduled alling ompleted									

Referral management	• There is <u>NOT</u> a systematic approach to track refer					 There is a systematic approach to track referrals including: How many referrals become scheduled appointments Number of visits that were referrals Referral source Reason for referral 					
Scheduling assistance (Check all that apply)		There is NOT support staff or processes in place to assist with CMM scheduling		There is a consistent scheduling processes in place solely managed by the pharmacist including:		There is CMM scheduling assistance (i.e., the pharmacist is not solely responsible) with: □ Centralized scheduling □ Local/clinic-level scheduling □ Preparing patients for visits/setting expectations □ Reminder calls □ Ensuring referrals get scheduled □ Ensuring follow-up appointments get scheduled	□ Patients can schedule their own CMM appointments online				
Outreach	 Currently <u>NO</u> outreach strategies are utilized to schedule eligible patients for CMM 				 Outreach strategies are in place to schedule eligible patients for CMM including: Outbound calling Letters Other mailings (e.g. brochure) Electronic messaging (e.g., portal messaging) Other 						

Documentation				
Documentation system access	Pharmacists document CMM O Pharmacists document CMM visits visits in a system visible ONLY in a system visible ONLY to the	harmacists document CMM isits in an EHR that the rest of ne care team uses		
Double documenting	Pharmacists document components of CMM visits in more than one system o Pharmacists document A fractional system	ALL components of CMM visits		
Documentation completion		nsistently held accountable for r CMM visit notes within a defined thin 24 hours of visit)		
Documentation efficiency • EHR tools (Check all that apply)	majority of their CMM notesEHR can be auto-populated into(eusing free textCMM notes (e.g. dot phrases)reoror	here is clinical decision support e.g., computerized alerts and eminders, condition-specific rder sets) built into CMM ocumentation		
Documentation efficiencyInputting notes (Check all that apply)	individually typing the majority of transcription tools (e.g. Dragon) of CMM notes transcription tools (e.g. Dragon) transcription transcription tools (e.g. Dragon) transcripti	harmacists dictate the majority f CMM notes which a ranscriptionist transcribes <u>OR</u> ave a scribe present during the najority of CMM visits		
Medication therapy problems (MTPs)	document medication therapy medication therapy problems do	harmacists consistently ocument medication therapy roblems <u>AND</u> their resolution		

Documentation improvement initiatives	0	Pharmacists do NOT review docur processes to identify areas for impro regular basis			• Pharmacists review documentation processes to identify areas for improvement on a regular basis					
(e.g., documentation committees to create documentation shortcuts or enlisting the services of EHR experts to learn efficiency tools; <u>NOT</u> peer chart reviews)										
IT support to modify documentation processes	0	Pharmacists do <u>NOT</u> have IT support to modify documentation processes	0	BUT requests	are ane	ntion processes, not completed and/or not all	0	Pharmacists have IT support to modify documentation processes and requests are completed in a timely manner and most requests are accepted		
Require a physician's co- signature	0	Pharmacist documentation <u>REQU</u> provider co-signature	IRE	<u>S</u> another	0	Pharmacist docu provider co-sign		ntation is final <u>WITHOUT</u> another e		

CMM Program Evaluation

Directions: Listed below are the essential components of CMM program evaluation. For each item listed under the essential component, mark the box that best describes your current CMM practice.

	Less optimal Optim											
Measuring CMM	pı	ogram data										
Medication therapy problems (MTPs) • Identification	0	The identification of MTPs are <u>NOT</u> tracked for the entire CMM population	0	The number of MTPs identified are tracked for the entire CMM population	0	The number <u>AND</u> types of MTPs identified are tracked for the entire CMM population						
Medication therapy problems • Resolution	0	The resolution of MTPs are <u>NOT</u> tracked for the entire CMM population	0	The number of MTPs resolved are tracked for the entire CMM population	0	The number <u>AND</u> types of MTPs resolved are tracked for the entire CMM population						
Clinical markers (e.g., ACT score, blood pressure, A1C)	0	Clinical markers are <u>NOT</u> tracked for the entire CMM population	0	Clinical markers are tracked for the entire CMM population periodically when deemed <u>necessary</u>	0	Clinical markers are tracked for the entire CMM population consistently and frequently						
Fiscal measures Revenue generated 	0	CMM revenue generated is NOT tracked	0	CMM revenue generated is tracked periodically when <u>deemed necessary</u>	0	CMM revenue generated is tracked <u>consistently and</u> <u>frequently</u>						
Fiscal measuresEstimated cost savings	0	Estimated cost savings through CMM is NOT tracked	0	Estimated cost savings through CMM is tracked periodically when deemed necessary	0	Estimated cost savings through CMM is tracked <u>consistently</u> <u>and frequently</u>						
Descriptive measures (e.g., payer mix, number of medications patients are taking, types of conditions seen in CMM population)	0	Descriptive measures of the entire of population are <u>NOT</u> tracked	CMN	M patient O Descriptive m population are		res of the entire CMM patient cked						

Pharmacist productivity	0	CMM pharmacist productivity is NOT tracked Patient satisfaction of CMM is o Patient satisfaction							 CMM pharmacist productivity is tracked including: Time spent in patient care Charting time Number of interventions to prevent and resolve MTPs Types of interventions to prevent and resolve MTPs Patient volume (e.g., number of CMM visits) 					
Patient satisfaction	0	Patient satisfaction of CMM is <u>NOT</u> assessed					atient satisfaction of CMM is o Patient satisfa ssessed, <u>BUT NOT</u> regularly regularly asses						ction of CMM is sed	
Provider/team satisfaction	0	Provider or team sa CMM is <u>NOT</u> asses		tion with	0	СМ	ovider or tear IM is assesse ularly				der or team satisfaction with is regularly assessed			
Pharmacist satisfaction	0	Pharmacist job satisfaction is <u>NOT</u> assessed	-	satisf	macist job action is assessed, <u>' NOT</u> regularly			 Pharmacist job satisfaction is regularly assessed 				 Pharmacist job satisfaction that <u>includes questions</u> <u>specific to CMM</u> is regularly assessed 		
Use of CMM collected data (e.g., clinical, descriptive, or financial data) (Check all that apply)		There is <u>NOT</u> a consistent strategy to use CMM data		CMM data used to me third party compliance requireme (e.g., in ca audit)	eet re nts	f	□ CMM c used to CMM s (e.g., to pharma FTEs)	descri ervices justify	es CMM service				CMM data is used to demonstrate value of CMM services (e.g., to senior leadership and external partners)	
Reporting CMM	da	ta and outcon	nes											
Reporting data (e.g., clinical outcomes, patient satisfaction) (Check all that apply)		<u>NOT</u> reported	repo withi	M data is rted in the M team		rep	IM data is orted hin the iic	C re	Pertinent CMM data is eported to eadership	CM rep acr	tinent IM data orted oss the anizatio		 CMM data is reported externally (e.g., meetings and publications) 	

Data extraction (Check all that apply)		CMM data is <u>NOT</u> extracted		extra	M data is acted, but <u>ONLY</u> ugh manual chart ew		Some CMM d extracted thro automated rep	ugh	 Most CMM data is extracted through automated reports
Extracting aggregate-level data	0	It is <u>NOT</u> possible to extract aggregate-level CMM data from the documentation system through an automated process			• It is possible to extract aggregate-level data from the documentation system through an automated process				
Extracting patient- level data	0	It is NOT possible to extract patient-level CMM data from the documentation system through an automated process			• It is possible to extract patient-level CMM data from the documentation system through an automated process				
IT support for extracting data	0	There is <u>NOT</u> IT support available to complete CMM requests	IT	• There is IT support T complete CMM IT requests often take desired to complete		f requests, <u>BUT</u> e longer than		comp	is IT support available to lete CMM IT requests in a manner

Ensuring Consistent and Quality Care

Directions: Listed below are the essential components of ensuring consistent and quality care. For each item listed under the essential component, mark the box that best describes vour current CMM practice.

Less optimal

Optimal

_									
Practitioner training									
 Training process CMM philosophy of practice 	• There is <u>NOT</u> a standard process in place for training newly hired CMM pharmacists (excluding residents) on CMM philosophy of practice	• There is a standard process in place for training newly hired CMM pharmacists (excluding residents) on CMM philosophy of practice							
 Training process CMM patient care process (e.g., reviewing mock cases, shadowing opportunities) 	• There is <u>NOT</u> a standard process in place for training newly hired CMM pharmacists (excluding residents) on the CMM patient care process	 There is a standard process in place for training newly hired CMM pharmacists (excluding residents) on the CMM patient care process 							
Training processCMM practice management	• There is <u>NOT</u> a standard process in place for training newly hired CMM pharmacists (excluding residents) on CMM practice management	• There is a standard process in place for training newly hired CMM pharmacists (excluding residents) on CMM practice management							
Trainer	• There is <u>NOT</u> a consistent trainer for training all newly hired CMM pharmacists	• There is a consistent trainer for training all newly hired CMM team members							
Ongoing clinical development (Check all that apply)	□ There is NOT a standard process for ongoing pharmacist CMM development □ The organization facilitates topics (e.g., journal clubs, speakers) for ongoing CMM development	 Pharmacists are required to have individualized professional development plans for ongoing CMM development (beyond CE) Pharmacists are required to have individualized provided resources (e.g., time or monies) to support learning plans 							

Continual policy, procedure, and standards of practice training (e.g., documentation standards, regulatory requirements)	pr reş H cre	blicy, procedure, and standards of cactice retraining is limited to gulatory requirements (e.g., IPAA, fraud waste and abuse) or redentialing as needed	0	Policy, procedur of practice retra regulatory requirements/cr documentation as needed	ining redei	g (beyond ntialing) (e.g.,	0	Policy, procedure, and standards of practice retraining (beyond regulatory/credentialing) occurs on a consistent basis
Quality assurance (QA) processes								
Ensuring pharmacists are providing consistent and quality care (e.g., peer review)	as: pr	process is NOT in place to sess whether pharmacists are coviding consistent and quality are at least biannually	0	A process is in place to assess whether pharmacists are providing consistent and quality care at least biannually		0	A process is in place to assess whether pharmacists are providing consistent and quality care at least biannually WITH a consistent form	
Ensuring notes have met documentation requirements (e.g., chart audits)	ph	process is <u>NOT</u> in place for ensur- narmacists are meeting standards es ocumentation			0	 A process is in place for ensuring that pharmacists are meeting standards established for documentation 		
Using QA processes for improvement		Data from QA processes are <u>NOT</u> used to inform CMM improvement activities			• Data from QA processes are used to inform CMM improvement activities			

Part III – Prioritizing and Guiding Areas for Improvement

Directions: To identify potential areas of practice improvement, review the sections of the tool you have completed and identify 2-3 items that you consider to be your greatest area of need or opportunity. As a first step to guide your practice management improvement, complete the worksheet below.

What practice management items you would like to improve?	What is your goal?	How will this impact your practice?	What are the action steps to achieve this goal?	What people and resources do you need to achieve this goal?	Who will be responsible for the actions needed to achieve this goal?

Glossary

CMM: Comprehensive medication management

Collaborative visits: The primary care provider and the pharmacist seeing the patient at the same time or back-to-back provider/pharmacist visits

CPA: Collaborative practice agreement

CPT: Current procedural terminology

EHR: Electronic health record

Generated quality care lists: Lists or registries of patients that are generated based on quality measures

IT: Information technology

LPN: Licensed practical nurse

MA: Medical assistant

MTM: Medication therapy management

MTPs: Medication therapy problems

Patient panel: A list of all patients receiving CMM

QA: Quality assurance

For more information, please contact:

Debbie Pestka, PharmD 7-191 Weaver-Densford Hall 308 Harvard Street SE Minneapolis, MN 55455 Telephone: 612-626-9938 Email: <u>pestk003@umn.edu</u>